Szalay et al. analyzed proportions of CCR6+ Th17 cells in subjects with established RA before and after 8 weeks of anti-TNF therapy, and found no significant change in the Th17 population37, similar to our findings. This evidence concerns the gene CCR6 and rheumatoid arthritis.